CAJ | 학술논문

目的：观察贞芪益气胶囊联合GP方案（吉西他滨+顺铂）治疗晚期非小细胞肺癌的近期临床疗效、毒性反应及其对无进展生存期的影响。方法：将晚期非小细胞肺癌患者67例随机分为治疗组34例和对照组33例。治疗组应用贞芪益气胶囊联合GP方案治疗,对照组单用GP方案治疗，每21天为1个周期，治疗4周期后观察疗效。结果：治疗组有效率和疾病控制率分别为47.1%、79.4%，高于对照组的39.4%、63.6%,但无统计学意义(P＞0.05)；治疗组患者生活质量及症状改善情况优于对照组,2组比较差异具有统计学意义(P＜0.05)；治疗组白细胞减少及恶心、呕吐例数明显低于对照组(P＜0.05)；2组无进展生存期比较，差异具有统计学意义(P＜0.05)。结论：贞芪益气胶囊联合GP方案能改善晚期非小细胞肺癌患者症状,减轻化疗的毒性反应,提高患者生存质量，可延长患者的无进展生存期。
목적：관찰정기익기효낭연합GP방안（길서타빈+순박）치료만기비소세포폐암적근기림상료효、독성반응급기대무진전생존기적영향。방법：장만기비소세포폐암환자67례수궤분위치료조34례화대조조33례。치료조응용정기익기효낭연합GP방안치료,대조조단용GP방안치료，매21천위1개주기，치료4주기후관찰료효。결과：치료조유효솔화질병공제솔분별위47.1%、79.4%，고우대조조적39.4%、63.6%,단무통계학의의(P＞0.05)；치료조환자생활질량급증상개선정황우우대조조,2조비교차이구유통계학의의(P＜0.05)；치료조백세포감소급악심、구토례수명현저우대조조(P＜0.05)；2조무진전생존기비교，차이구유통계학의의(P＜0.05)。결론：정기익기효낭연합GP방안능개선만기비소세포폐암환자증상,감경화료적독성반응,제고환자생존질량，가연장환자적무진전생존기。
Objective:To observe short-term effects and toxicity of ZhenQi YiQi capsule combined with GP regimen (gemcitabine and cis-platinum complexes) in treating advanced non-small-cell lung cancer, and its effects on progression-free survival. Methods:Sixty-seven patients were randomized into 34 cases of the treatment group and 33 cases of the control group. The treatment group were given with ZhenQi YiQi capsule combined with GP regimen, and the control group GP regimen. 21 days were one course of the treatment, curative effects were ob-served after treating for four courses of the treatment. Results:Effective rate and disease control rate of the treatment group were 47.1%and 79.41%respectively, higher than 39.4%and 63.63%of the control group, but the comparison had no statistical meaning (P>0.05);life quality and symptom improvements of the patients in the treatment group were superior to these of the control group, the difference presented statistical meaning (P<0.05); the treatment group was obviously lower than the control group in the cases with leucopenia, nausea and vorniting (P<0.05);the difference had statistical meaning in the comparison of progression-free survival between both groups (P<0.05). Conclusion:ZhenQi YiQi capsule combined with GP regimen could improve the symptoms of the patients with ad-vanced non-small-cell lung cancer, relieve the toxicity of chemotherapy, raise life quality of the patients and prolong progression-free survival of the patients.